KRAS and oral cavity squamous cell carcinoma: In addition, SCH772984 plus apatinib has been effective against oral squamous cell carcinoma (OSCC) [45], and SCH772984 is also an alternative for the treatment of LKB1 and LKB1/KRAS-mutated NSCLC [46].